Human single-chain antibodies inhibit replication of human immunodeficiency virus type 1 (HIV-1). 2005

Fangbing Liu, and Mukesh Kumar, and Qiangzhong Ma, and Mark Duval, and David Kuhrt, and Richard Junghans, and Marshall Posner, and Lisa Cavacini
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.

The F240 human monoclonal antibody specifically recognizes the disulfide loop-bonded immunodominant epitope of gp41 spanning residues 592-606 and expressed broadly on HIV-1 primary isolates. Despite broad reactivity with native virions and HIV-infected cells, the antibody fails to neutralize infection. However, cytoplasmic expression of single-chain antibody (scFv) directed against gp41 of HIV-1 provides a rationale means to inhibit the maturation of envelope protein. The variable regions of the heavy chain and light chain of human monoclonal antibody were amplified by PCR and linked by a 15 amino acid (GGSGS)3 linker in an orientation of VL-linker-VH and retroviral expression vectors were constructed to simultaneously express F240 scFv and eGFP to facilitate selection of scFv-producing cells. Incorporation of a human immunoglobulin signal sequence directed secretion of the F240 scFv (s-scFv) while an otherwise identical vector lacked this sequence (scFv) resulting in intracellular expression of scFv. Transduced human CD4+ H9 T cells were challenged with HIV. While both secreted and nonsecreted F240 scFv inhibited viral production, secretory F240 scFv was more potent. Thus, this novel approach to direct expression of a nonneutralizing scFv using the Ig signal sequence suggests that targeted therapy using antibodies to conserved, highly expressed epitopes may result in a decrease in viral production due to a reduction of viral assembly and/or transport and expression.

UI MeSH Term Description Entries
D007135 Immunoglobulin Variable Region That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions. Variable Region, Ig,Variable Region, Immunoglobulin,Framework Region, Immunoglobulin,Fv Antibody Fragments,Fv Fragments,Ig Framework Region,Ig Variable Region,Immunoglobulin Framework Region,Immunoglobulin Fv Fragments,Immunoglobulin V,Antibody Fragment, Fv,Antibody Fragments, Fv,Fragment, Fv,Fragment, Fv Antibody,Fragment, Immunoglobulin Fv,Fragments, Fv,Fragments, Fv Antibody,Fragments, Immunoglobulin Fv,Framework Region, Ig,Framework Regions, Ig,Framework Regions, Immunoglobulin,Fv Antibody Fragment,Fv Fragment,Fv Fragment, Immunoglobulin,Fv Fragments, Immunoglobulin,Ig Framework Regions,Ig Variable Regions,Immunoglobulin Framework Regions,Immunoglobulin Fv Fragment,Immunoglobulin Variable Regions,Regions, Immunoglobulin Variable,Variable Regions, Ig,Variable Regions, Immunoglobulin
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015700 HIV Envelope Protein gp41 Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING. Envelope Protein gp41, HIV,HIV Transmembrane Protein gp41,HTLV-III gp41,env Protein gp41, HIV,gp41(HIV),gp41 Envelope Protein, HIV
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Fangbing Liu, and Mukesh Kumar, and Qiangzhong Ma, and Mark Duval, and David Kuhrt, and Richard Junghans, and Marshall Posner, and Lisa Cavacini
January 2011, Bioorganic & medicinal chemistry letters,
Fangbing Liu, and Mukesh Kumar, and Qiangzhong Ma, and Mark Duval, and David Kuhrt, and Richard Junghans, and Marshall Posner, and Lisa Cavacini
October 1995, The Journal of infectious diseases,
Fangbing Liu, and Mukesh Kumar, and Qiangzhong Ma, and Mark Duval, and David Kuhrt, and Richard Junghans, and Marshall Posner, and Lisa Cavacini
August 2002, Journal of medicinal chemistry,
Fangbing Liu, and Mukesh Kumar, and Qiangzhong Ma, and Mark Duval, and David Kuhrt, and Richard Junghans, and Marshall Posner, and Lisa Cavacini
February 1999, Pharmacotherapy,
Fangbing Liu, and Mukesh Kumar, and Qiangzhong Ma, and Mark Duval, and David Kuhrt, and Richard Junghans, and Marshall Posner, and Lisa Cavacini
September 1994, Antiviral research,
Fangbing Liu, and Mukesh Kumar, and Qiangzhong Ma, and Mark Duval, and David Kuhrt, and Richard Junghans, and Marshall Posner, and Lisa Cavacini
February 2011, Virologie (Montrouge, France),
Fangbing Liu, and Mukesh Kumar, and Qiangzhong Ma, and Mark Duval, and David Kuhrt, and Richard Junghans, and Marshall Posner, and Lisa Cavacini
January 1995, Journal of cellular biochemistry. Supplement,
Fangbing Liu, and Mukesh Kumar, and Qiangzhong Ma, and Mark Duval, and David Kuhrt, and Richard Junghans, and Marshall Posner, and Lisa Cavacini
June 2006, Journal of virology,
Fangbing Liu, and Mukesh Kumar, and Qiangzhong Ma, and Mark Duval, and David Kuhrt, and Richard Junghans, and Marshall Posner, and Lisa Cavacini
October 2002, Croatian medical journal,
Fangbing Liu, and Mukesh Kumar, and Qiangzhong Ma, and Mark Duval, and David Kuhrt, and Richard Junghans, and Marshall Posner, and Lisa Cavacini
August 1998, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!